<DOC>
	<DOCNO>NCT00032097</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Drugs motexafin gadolinium may make tumor cell sensitive radiation therapy . PURPOSE : Phase I trial study effectiveness motexafin gadolinium treat patient glioblastoma multiforme undergo radiation therapy brain .</brief_summary>
	<brief_title>Motexafin Gadolinium Treating Patients With Glioblastoma Multiforme Who Are Undergoing Radiation Therapy Brain</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxicity 2 different schedule motexafin gadolinium radiosensitizer patient glioblastoma multiforme receive cranial radiotherapy . - Determine maximum tolerated dos drug 2 schedule patient . - Determine pharmacokinetic profile drug patient . - Determine biodistribution drug neoplastic tissue normal brain parenchyma patient . - Determine effect accumulation drug normal brain parenchyma neoplastic tissue patient . - Correlate effect accumulation drug normal brain parenchyma neoplastic tissue pharmacokinetics drug patient . OUTLINE : This multicenter , dose-escalation study motexafin gadolinium ( PCI-0120 ) . Patients sequentially assign 1 2 treatment group . - Group I : Patients receive PCI-0120 IV 30-60 minute every day 6 week . Patients concurrently undergo cranial radiotherapy daily 5 day week 6 week . - Group II : Patients receive PCI-0120 IV 30-60 minute daily concurrently radiotherapy . Patients undergo cranial radiotherapy group I . Cohorts 3-6 patient group receive escalate dos PCI-0120 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Patients follow 1 month every 2 month thereafter . PROJECTED ACCRUAL : Approximately 18-30 patient accrue study .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Motexafin gadolinium</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm supratentorial grade IV astrocytoma Glioblastoma multiforme Previously untreated disease Measurable contrastenhancing tumor MRI incomplete resection/biopsy PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm^3 Absolute granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 10 g/dL Hepatic : Bilirubin great 2.0 mg/dL SGOT/SGPT great 4 time upper limit normal ( ULN ) Alkaline phosphatase great 4 time ULN PT/APTT normal Renal : Creatinine great 1.5 mg/dL Cardiovascular : No uncontrolled hypertension Other : Mini mental state exam score least 15 No history glucose6phosphate dehydrogenase deficiency porphyria No malignancy within past 5 year except curatively treat basal cell squamous cell skin cancer , carcinoma situ cervix , carcinoma situ breast No serious infection No medical illness would preclude study participation No allergy MRI contrast ( e.g. , motexafin gadolinium ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 2 month study PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic therapy immunotherapy disease , include follow : Immunotoxins Immunoconjugates Antisense therapy Peptide receptor antagonist Interferons Interleukins Tumorinfiltrating lymphocyte Lymphokineactivated killer cell therapy Gene therapy Chemotherapy : No prior chemotherapy disease Endocrine therapy : Must stable corticosteroid regimen ( i.e. , increase within 5 day prior treatment protocol ) No prior hormonal therapy disease Radiotherapy : No prior radiotherapy disease Surgery : See Disease Characteristics Recovered prior surgery Other : No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2004</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>